Chronic Lymphocytic Leukemia News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Umbraslisib Shows Early Promise in CLL and Lymphoma - OncLive - OncLive



OncLive
 
Umbraslisib Shows Early Promise in CLL and Lymphoma - OncLive 
OncLive
The PI3K-delta inhibitor umbralisib (TGR-1202) induced an objective response rate (ORR) of 37% in patients with relapsed/refractory lymphoma or chronic lymphocytic leukemia (CLL), according to phase I findings published in The Lancet Oncology.1. In the ...
Umbralisib: A Promising Therapy for Hematologic Malignancies ... Cancer Therapy Advisor

all 2 news articles » 


B-Cell Chronic Lymphocytic Leukemia Market Growth and Technologies Research Report - The Financial



B-Cell Chronic Lymphocytic Leukemia Market Growth and Technologies Research Report 
The Financial
?B-Cell Chronic Lymphocytic Leukemia- Pipeline Insight, 2018?offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across B-Cell Chronic Lymphocytic Leukemia development. The report provides ...

 


Relapsed Chronic Lymphocytic Leukemia (CLL) Market 2018 Product Description: Growth, Trends, Company Profiles ... - The Financial



Relapsed Chronic Lymphocytic Leukemia (CLL) Market 2018 Product Description: Growth, Trends, Company Profiles ... 
The Financial
Relapsed Chronic Lymphocytic Leukemia (CLL) Market Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 ? marketed, Phase III products, Drugs Profiles and route of synthesis. The Relapsed Chronic Lymphocytic Leukemia (CLL) Market ...

and more » 


Current Approaches to Diagnosis and Risk Stratification in CLL - Targeted Oncology



Targeted Oncology
 
Current Approaches to Diagnosis and Risk Stratification in CLL 
Targeted Oncology
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) is a malignancy characterized by the clonal proliferation and accumulation of small, mature-appearing CD5-positive B lymphocytes in the blood, bone marrow, and secondary lymphoid tissues.1 A CLL diagnosis is ...

and more » 


B-Cell Chronic Lymphocytic Leukemia Market 2018 Global Trend, Segmentation, Key Manufacturers and Opportunities ... - The Financial



B-Cell Chronic Lymphocytic Leukemia Market 2018 Global Trend, Segmentation, Key Manufacturers and Opportunities ... 
The Financial
B-Cell Chronic Lymphocytic Leukemia Market Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018 ? marketed, Phase III products, Drugs Profiles and route of synthesis. The B-Cell Chronic Lymphocytic Leukemia Market report is an in ...

and more » 


B-Cell Chronic Lymphocytic Leukemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape Report ... - Business Wire (press release)



B-Cell Chronic Lymphocytic Leukemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape Report ... 
Business Wire (press release)
B-Cell Chronic Lymphocytic Leukemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018' report provides comprehensive insights about marketed and Phase III products for B-Cell Chronic Lymphocytic Leukemia . The report includes ...

and more » 


Single-Agent Ibrutinib Active at 5 Years in CLL, SLL - Cancer Network



Single-Agent Ibrutinib Active at 5 Years in CLL, SLL 
Cancer Network
Treatment with single-agent ibrutinib resulted in sustained efficacy and durable responses in patients with treatment-naive or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to recently ...

 


Factors Affecting Prognosis and Treatment in CLL - Targeted Oncology



Targeted Oncology
 
Factors Affecting Prognosis and Treatment in CLL 
Targeted Oncology
In 2008, the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) published revised guidelines for the diagnosis and treatment of CLL.6 These revised guidelines acted as an update to the National Cancer Institute sponsored Working Group's ...

and more » 


Genomics in Chronic Lymphocytic Leukemia: Current Research & Future Implications - LWW Journals



Genomics in Chronic Lymphocytic Leukemia: Current Research & Future Implications 
LWW Journals
An initially slow-growing common B-cell malignancy with a variable clinical course, chronic lymphocytic leukemia (CLL) represents the most common hematological neoplasm in the developed world (Hematol Oncol Clin North Am 2013;27(2):173-206). Although ...

and more » 


Combinations Continue to Push CLL Field Forward - OncLive



OncLive
 
Combinations Continue to Push CLL Field Forward 
OncLive
OncLive: Can you discuss the impact of recent combination trials in CLL? Barrientos: We are trying to get deeper responses than what we have seen with regular use of a B-cell receptor signaling agent. Moving forward, data such as from the TAP CLARITY ...